SC
IOBT

Steven Cohen’s IO Biotech IOBT Stock Holding History

Steven Cohen’s Portfolio IOBT Stock Details IOBT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q4 		– Sell
-250,000
Closed -$90.8K – 4028
2025
Q3 		$90.8K Buy
+250,000
New +$431K ﹤0.01% 2213
2023
Q2 		– Sell
-1,400,000
Closed -$2.63M – 2462
2023
Q1 		$2.63M Buy
+1,400,000
New +$3.49M 0.01% 929

Other funds holding IOBT

NHAS
Novo Holdings A/S Hellerup, Denmark $1.72B AUM 106.92% 1-Year Est. Return
IC
Ikarian Capital Dallas, Texas $928M AUM 596.14% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.55T AUM 33.47% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
BPA
Beacon Pointe Advisors Newport Beach, California $21.5B AUM 23.65% 1-Year Est. Return
BFM
Boothbay Fund Management New York $7.6B AUM 109.3% 1-Year Est. Return
DIG
Dauntless Investment Group Etna, New Hampshire $127M AUM 42.43% 1-Year Est. Return
Marshall Wace
Marshall Wace London, United Kingdom $127B AUM 46.06% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return
Millennium Management
Millennium Management New York $276B AUM 44.8% 1-Year Est. Return

Steven Cohen's IOBT Position: Q4 2025 in Review

Steven Cohen sold out of IO Biotech (IOBT) in Q4 2025, closing a stake of 250,000 shares — an estimated $90.8K sold.

Steven Cohen first reported a position in IOBT in Q1 2023 and held it in 2 quarters. The position peaked at $2.63M in Q1 2023. 22 funds tracked by Wall St. Rank hold IOBT as of Q4 2025.

  • Steven Cohen reported no remaining IO Biotech position as of Q4 2025 after selling out during the quarter.
  • Steven Cohen sold 250,000 IO Biotech shares in Q4 2025, an estimated $90.8K.
  • Steven Cohen first reported a position in IO Biotech in Q1 2023 and held it in 2 quarters.
  • Steven Cohen's IO Biotech position peaked at $2.63M in Q1 2023.
  • 22 funds tracked by Wall St. Rank held IO Biotech as of Q4 2025.

Based on Point72 Asset Management's 13F filing for Q4 2025, filed 17 Feb 2026.